真性红细胞增多症 中国就医指南

Polycythemia Vera (PV) is a chronic, clonal myeloproliferative neoplasm characterized by the overproduction of red blood cells (erythrocytosis), often accompanied by elevated white blood cell and platelet counts. It arises from a somatic gain-of-function mutation in the JAK2 gene—most commonly JAK2 V617F—in hematopoietic stem cells, leading to cytokine-independent activation of the JAK-STAT signaling pathway. This results in uncontrolled proliferation of erythroid precursors in the bone marrow, independent of erythropoietin (EPO) regulation. PV is not inherited but acquired, and while its exact triggers remain unclear, aging is the strongest known risk factor; the median age at diagnosis is 60–65 years. Epidemiologically, PV has an annual incidence of approximately 0.4–2.8 cases per 100,000 people, with a slight male predominance (male-to-female ratio ~1.3:1). It is rare in children and adolescents. Risk factors include advanced age, prior exposure to ionizing radiation (limited evidence), and possibly certain occupational chemical exposures—though no definitive environmental or lifestyle modifiable risks have been established. Untreated PV significantly increases the risk of life-threatening thrombotic events—including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke—as well as hemorrhagic complications, transformation to myelofibrosis (5–15% over 15 years), and acute myeloid leukemia (1–2% over 10 years). Symptoms are often insidious and nonspecific: headache, dizziness, visual disturbances (e.g., scintillating scotoma), pruritus (especially after warm showers), erythromelalgia (burning pain in hands/feet), fatigue, early satiety, and splenomegaly-related left upper quadrant discomfort. Many patients are asymptomatic at diagnosis and identified incidentally via routine blood tests showing elevated hemoglobin (>16.5 g/dL in men, >16.0 g/dL in women), hematocrit (>49% in men, >48% in women), and/or red blood cell mass. Quality of life is frequently impaired—not only by physical symptoms but also by anxiety related to thrombotic risk, treatment burden (e.g., lifelong phlebotomy, medication adherence), and psychosocial impact of a chronic hematologic malignancy. Fatigue remains one of the most prevalent and debilitating patient-reported outcomes, even in well-controlled disease. Effective management aims to reduce thrombotic risk through cytoreduction, symptom control, and vigilant monitoring for disease progression. Early diagnosis and individualized, long-term care by specialized hematologists are essential to preserve survival (median overall survival exceeds 14–20 years with modern therapy) and maintain functional quality of life.

# 真性红细胞增多症（PV）治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

适用人群：初诊低危患者（年龄＜60岁、无血栓史、JAK2 V617F阳性）、老年或合并基础病者。

• •静脉放血（Phlebotomy）：每2–4周1次，目标Hct＜45%；含血常规+铁蛋白监测；单次费用：380–650元（含采血、检测、耗材）。
• •羟基脲（一线药物）：口服，起始剂量20–30 mg/kg/d；需每月血常规+肝肾功能；年药费：2,400–4,800元（国产仿制药）。
• •干扰素α（PEG-IFNα）：适用于育龄期或羟基脲不耐受者；年治疗费：68,000–92,000元（含皮下注射指导、骨髓活检随访）。

二、核心介入/根治性方案

适用人群：高危患者（年龄≥60岁或既往血栓）、进展为骨髓纤维化或急性白血病者。

• •异基因造血干细胞移植（Allo-HSCT）：唯一潜在根治手段；需HLA配型、供者筛选、预处理及移植后长期免疫抑制；全流程费用：32–45万元（含术前检查：染色体核型+NGS+MRD检测等，检查费：8,200–12,500元）。

三、特殊复杂情况方案

• •耐药/进展期PV：联合芦可替尼+阿那格雷；年药费：18.6–24.5万元（医保谈判后自付约3.2–5.1万元）。
• •PV相关血栓急性期：肝素抗凝+溶栓（如尿激酶），住院5–10天总费用：15,000–32,000元。

四、方案快速选择指南

• •预算＜5,000元/年：首选静脉放血+羟基脲（基层医院可执行）；
• •追求疾病修饰/年轻患者：PEG-IFNα（兼顾安全性与克隆控制）；
• •高危进展或继发AML：评估Allo-HSCT（推荐至国家级血液中心）。